ROCHE
Glofitamab for diffuse large B-cell lymphoma (DLBCL)
Roche announced that new pivotal data on glofitamab will be presented at ASCO 2022. Glofitamab is a CD20xCD3 T-cell engaging bispecific antibody.
In Phase 2 NP30179 study, patients who were heavily pre-treated for refractory DLBCL were included. After a median follow-up of 12.6 months, 39.4% of patients achieved complete response, and half achieved an overall response.
BMS
Breyanzi for LBCL
BMS announced the Phase 2 PILOT study, which demonstrated the durable response of Breyanzi (lisocabtagene maraleucel) in adult patients with refractory or relapsed large B-cell lymphoma (LBCL). Patients previously treated with first-line therapy and are not candidates for high dose chemotherapy or hematopoietic stem cell transplant (HSCT) were included in the trial.
The PILOT study included adults with refractory or relapsed LBCL after first-line therapy. After a median follow-up of 12.3 months, 80% showed response to treatment, and 54% of patients showed complete response. The median duration of response was 21.7 months in patients who achieved complete response, median progression-free survival was 9.0 months, and median overall survival was not reached.
NOVARTIS
Scemblix for CML
Novartis presented superior and long-term data of Scemblix (asciminib) in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Scemblix showed superior efficacy versus Bosulif (bosutinib) at 96 weeks in terms of major molecular response (37.6% vs. 15.8%) in the Phase III ASCEMBL trial in patients treated with two or tyrosine kinase inhibitors.
Further, Novartis announced that the discontinuation due to adverse events was three times lesser in Scemblix than Bosulif.
Scemblix is the first therapy approved by the FDA that acts by inhibiting the ABL myristoyl pocket. Scemblix is a STAMP inhibitor that can address resistance to TKI inhibitors in patients with Ph+ CML.
Tafinlar + Mekinist for glioma
Novartis announced the Phase II/III study results of Tafinlar (dabrafenib) + Mekinist (trametinib) in pediatric patients of 1 to 17 years with BRAF V600 low-grade gliomas. The combination is given as a first-line systematic therapy in patients for whom chemotherapy is the standard of care.
Tafinlar plus Mekinist combination showed a statistically significant overall response rate versus chemotherapy (47% versus 11%). A liquid formulation was used in the trial. The median progression-free survival was 20.1 months in the Tafinlar + Mekinist combination versus 7.4 months in patients on chemotherapy. Nearly all patients had a reduction or no growth in tumor size compared to baseline versus 70% in patients on chemotherapy.
There were fewer discontinuations in the treatment because of the adverse events in Tafinlar + Mekinist arm compared to chemotherapy.
For pipeline, market overview, SLRs, and market access reports (syndicate and customized) please write to sales@firstviewinsight.com
Visit FirstViewInsight for more details
Comments